




CIN # L51900GJ1980PLC065554



SEPL/SE/Feb/24-25 10th February 2025

The General Manager, Corporate Relations/Listing Department BSE Limited

Floor 25, P.J. Towers, Dalal Street, Mumbai – 400 001

Scrip Code: 501423

The Manager,
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,

Bandra – Kurla Complex,

Bandra (E),

Mumbai – 400 051

Scrip Code: SHAILY

Sub: Q3FY25 - Result Presentation

Ref: Regulation 30 of the SEBI Listing Regulations, 2015

Dear Sir,

In continuation to our letter dated 4th February 2025, regarding intimation of Earnings Call of the Company scheduled on Monday, 10th February 2025, to discuss the Operational & Financial performance of the Company for the quarter and nine months ended on 31st December 2024, kindly find enclosed herewith **Q3FY25 Result Presentation** of the Company.

A copy of the same is also available on our website www.shaily.com.

Kindly take the same on record.

Thanking You.

Yours truly,

For Shaily Engineering Plastics Limited

Harish Punwani Company Secretary & Compliance Officer M. No. A50950

Encl: a/a



Safe Harbor



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Shaily Engineering Plastics Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.





Key Performance Highlights

Business Updates for Q3 FY25



Healthcare

Successful participant in Pharma Pack 2025, Paris

Participation in Pharma Pack exhibition in Paris to showcase our innovations in medical device space

Consumer

New Business awarded

Awarded business from 2 global retail chains and supplies to start from Q1/Q2 FY26

Healthcare

Signed 6 contracts for Pen Injectors

Signed 6 contracts with different customers for Pen Injectors for GLP 1 / Other therapies


Consumer

Successful participant in Cosmoprof, Mumbai

Participation in Cosmoprof exhibition in Mumbai to showcase our speciality packaging expertise

Key Financial Highlights - Q3 & 9M FY25 (Consolidated*)






(Rs. Cr.)


Key Financial Highlights - Q3 & 9M FY25 (Standalone)









Gross Profit Margin




EBITDA




EBITDA Margins





Profit After Tax





Cash PAT#







(Rs. Cr.)

Operational Trends







Profit & Loss Statement



Consolidated

Standalone

Particulars (Rs. Cr.)	Q3 FY25	Q3 FY24	YoY %	9M FY25	9M FY24	YoY %
Revenue	197.6	158.4	25%	569.0	473.3	20%
Raw Material	103.7	88.8		310.6	279.3	
Employee Expenses	19.6	14.7		57.2	41.5	
Other Expenses*	28.4	23.0		79.6	70.3	
Other Income	0.4	1.1		2.2	4.9	
EBITDA	46.3	33.0	40%	123.8	87.2	42%
EBITDA Margin	23.4%	20.8%		21.7%	18.4%	
Depreciation	10.7	9.4		31.1	25.7	
Finance Cost	4.1	5.0		13.0	13.2	
РВТ	31.5	18.6	70%	79.7	48.3	65%
PBT Margin	15.9%	11.7%		14.0%	10.2%	
Tax	6.3	4.0		15.1	10.3	
PAT	25.2	14.5	73%	64.5	38.0	70%
PAT Margin	12.8%	9.2%		11.3%	8.0%	
Cash PAT^	35.9	23.9	50%	95.6	63.6	50%
Cash PAT Margin	18.1%	15.1%		16.8%	13.4%	

Q3 FY25	Q3 FY24	YoY %	9M FY25	9M FY24	YoY %
186.3	144.7	29%	534.8	453.2	18%
103.7	88.8		310.6	279.3	
17.6	14.5		53.1	40.9	
27.0	20.2		75.5	66.5	
0.4	1.1		2.9	4.9	
38.5	22.2	73%	98.6	71.5	38%
20.6%	15.4%		18.4%	15.8%	
9.9	9.0		29.1	25.2	
4.1	5.0		13.0	13.2	
24.4	8.2	198%	56.5	33.0	71%
13.1%	5.7%		10.6%	7.3%	
6.3	2.0		15.1	8.3	
18.1	6.2	192%	41.4	24.7	67%
9.7%	4.3%		7.7%	5.5%	
28.0	15.3	83%	70.4	50.0	41%
15.0%	10.6%		13.2%	11.0%	

Balance Sheet



Particulars (Rs. Crs.)	Sep-24	Mar-24
Non-Current assets		
Property, Plant and Equipments	429.6	435.4
Capital Work in Process	26.7	15.3
Intangible assets	36.0	38.0
Investments	0.0	0.0
Intangible assets under development	8.6	5.1
Financial Assets		
Loans	0.5	0.5
Other Non-Current Assets	20.1	18.3
Income tax assets	1.2	2.7
Total Non-Current Assets	522.6	515.3
Current Assets		
Inventories	101.7	83.6
Financial Assets		
Trade Receivables	136.7	117.4
Cash and Cash Equivalents	15.0	26.4
Loans	0.5	6.4
Other Current Assets	38.7	33.5
Current tax assets (Net)	0.0	0.0
Total Current Assets	292.6	267.2
Total Assets	815.2	782.5

Particulars (Rs. Crs.)	Sep-24	Mar-24
Equity		
Equity Share Capital	9.2	9.2
Other Equity	485.6	450.0
Total Equity	494.8	459.2
Non-Current Liabilities		
Financial Liabilities		
Long-term borrowings	53.2	69.8
Deferred tax liabilities (net)	23.0	20.8
Other long-term liabilities	0.4	1.2
Long-term provisions	2.6	2.2
Total Non-Current Liabilities	79.2	94.1
Current Liabilities		
Short-term borrowings	122.2	138.5
Trade payables	91.7	68.7
Other financial liabilities	9.8	10.3
Other current liabilities	12.2	10.4
Short-term provisions	4.7	1.3
Current tax liabilities (net)	0.7	0.0
Total Current Liabilities	241.2	229.2
Total Equity and Liabilities	815.2	782.5

On Consolidated basis

Balance Sheet



Particulars	Sep-24	Mar-24
Non-Current assets		
Property, Plant and Equipments	428.4	434.9
Capital Work in Process	26.7	15.3
Intangible assets	16.8	17.8
Investments	11.3	20.6
Intangible assets under development	3.5	2.1
Financial Assets		
Loans	0.5	0.5
Other Non-Current Assets	20.1	18.3
Income tax assets	0.0	2.3
Total Non-Current Assets	507.2	511.8
Current Assets		
Inventories	101.7	83.6
Financial Assets		
Trade Receivables	113.8	111.7
Cash and Cash Equivalents	5.8	8.6
Loans	0.5	6.4
Other Current Assets	32.3	29.9
Current tax assets (Net)	0.0	0.0
Total Current Assets	254.1	240.3
Total Assets	761.3	752.1

Particulars	Sep-24	Mar-24
Equity		
Equity Share Capital	9.2	9.2
Other Equity	439.8	422.3
Total Equity	449.0	431.5
Non-Current Liabilities		
Financial Liabilities		
Long-term borrowings	53.2	69.8
Deferred tax liabilities (net)	21.9	20.4
Other long-term liabilities	0.4	1.2
Long-term provisions	2.6	2.2
Total Non-Current Liabilities	78.1	93.6
Current Liabilities		
Short-term borrowings	122.2	138.5
Trade payables	90.5	67.2
Other financial liabilities	9.8	10.3
Other current liabilities	6.4	9.7
Short-term provisions	4.7	1.3
Current tax liabilities (net)	0.7	0.0
Total Current Liabilities	234.2	227.0
Total Equity and Liabilities	761.3	752.1

On Standalone basis

Cash Flow Statement



Consolidated

Standalone


Particulars (Rs. Cr.)	H1 FY25	H1 FY24
Profit Before Tax	48.2	29.7
Adjustments	28.4	23.3
Operating profit before working capital changes	76.6	53.0
Changes in working capital	-6.6	-12.0
Cash generated from operations	69.9	41.0
Direct taxes paid (net of refund)	-3.6	-3.9
Net Cash from Operating Activities	66.3	37.1
Net Cash from Investing Activities	-32.2	-51.8
Net Cash from Financing Activities	-45.9	15.2
Net Change in cash and cash equivalents	-11.8	0.5
Add: Cash & Cash equivalents at the beginning of the period	22.2	19.1
Closing Cash Balance	10.4	19.6

H1 FY25	H1 FY24
32.1	24.8
23.8	23.2
55.9	48.0
9.5	-8.5
65.4	39.4
-3.6	-3.9
61.8	35.6
-19.2	-54.6
-45.9	15.2
-3.3	-3.8
4.4	17.7
1.2	13.9

On Consolidated basis

Efficient Use of Capital





About the Company



Enriching Lives Through Plastics



Shaily Engineering Plastics Limited is India's largest exporter of plastics components. Established in 1987, the Company provides end-to-end solutions in plastic products and services, whilst delivering superior quality and value to all stakeholders.

The Company employs over 2,000+ employees and have over 200+ injection molding machines, with precise, high speed automated and robotic production lines.

Revenue*
Rs. 644 Crores
FY 24

7 Facilities in Gujarat

6 for Plastic 1 for Steel Furniture Long-standing global relationships with marquee clients

200+
Injection moulding machines


Over **2,000** employees across 7 plants

De-risked Business Model



Business Segments





- ✓ Home Furnishings
- ✓ FMCG Packaging

- ✓ LED Lights
 - ✓ Toys
- ✓ Carbon Steel Furniture

- ✓ Automotive Components
 - ✓ Appliances
 - ✓ High Performance
 Engineering Components

- ✓ Platform Devices
- ✓ Drug Delivery Devices
 - ✓ Pharma Packaging

State-of-the-Art Manufacturing Facilities



7 Facilities with over 200 molding machines ranging from 35 tons to 1,000 tons



Board of Directors



Executive Chairman

Mr. Mahendra Sanghvi

Whole Time Director

Ms. Tilottama Sanghvi

Managing Director

Mr. Amit Sanghvi

Executive Director

Mr. Laxman Sanghvi

Independent Director

Dr. Shailesh Ayyangar

Independent Director

Mr. Ranjit Singh

Independent Director

Mr. Samaresh Parida

Independent Director

Mrs. Sangeeta Singh

Strong Credit Rating*



LONG TERM BANK FACILITIES

Rs. 238.45 Crs.; reduced from Rs. 283 Crs.

CARE A; Outlook: Stable

Rating Action: Reaffirmed

SHORT TERM BANK FACILITIES

Rs. 35 Crs.

CARE A1

Rating Action: Reaffirmed



Long and established track record in the plastic injection molding business along with experienced Promoters



Growth in Total operating income on the back of increased volumes & higher exports



Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators



New business confirmations from existing clients along with addition of marquee clients across diversified industries



Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators

Historical Profit & Loss Statement



Consolidated

Standalone

Particulars (Rs. Cr.)	FY24	FY23
Revenue	643.9	607.1
Raw Material	370.1	386.5
Employee Expenses	57.3	47.9
Other Expenses*	99.5	80.8
Other Income	6.5	4.5
EBITDA	123.4	96.4
EBITDA Margin	19.2%	15.9%
Depreciation	35.7	33.3
Finance Cost	17.9	17.9
PBT	69.8	45.2
PBT Margin	10.8%	7.4%
Tax	12.6	10.1
PAT	57.3	35.1
PAT Margin	8.9%	5.8%
Cash PAT^	93.0	68.5
Cash PAT Margin	14.4%	11.3%

FY24	FY23
616.0	599.7
370.1	386.5
55.9	47.2
95.2	79.4
6.5	4.5
101.3	91.1
16.4%	15.2%
34.7	33.2
17.9	17.9
48.7	40.1
7.9%	6.7%
12.6	10.1
36.1	30.0
5.9%	5.0%
70.8	63.2
11.5%	10.5%

Historical Balance Sheet



Particulars	Mar-24	Mar-23
Non-Current assets		
Property, Plant and Equipments	435.4	347.9
Capital Work in Process	15.3	49.0
Intangible assets	38.0	19.0
Investments	0.0	0.0
Intangible assets under development	5.1	19.3
Financial Assets		
Loans	0.5	0.5
Other Non-Current Assets	18.3	17.2
Income tax assets	2.7	2.1
Total Non-Current Assets	515.3	455.0
Current Assets		
Inventories	83.6	73.0
Financial Assets		
Trade Receivables	117.4	91.9
Cash and Cash Equivalents	26.4	23.0
Loans	6.4	5.7
Other Current Assets	33.5	44.1
Current tax assets (Net)	0.0	0.0
Total Current Assets	267.2	237.7
Total Assets	782.5	692.7

Particulars	Mar-24	Mar-23
Equity		
Equity Share Capital	9.2	9.2
Other Equity	450.0	392.2
Total Equity	459.2	401.4
Non-Current Liabilities		
Financial Liabilities		
Long-term borrowings	69.8	62.5
Deferred tax liabilities (net)	20.8	17.0
Other long-term liabilities	1.2	1.2
Long-term provisions	2.2	2.3
Total Non-Current Liabilities	94.1	83.1
Current Liabilities		
Short-term borrowings	138.5	124.3
Trade payables	68.7	53.4
Other financial liabilities	10.3	9.3
Other current liabilities	10.4	20.0
Short-term provisions	1.3	1.2
Current tax liabilities (net)	0.0	0.0
Total Current Liabilities	229.2	208.2
Total Equity and Liabilities	782.5	692.7

On Consolidated basis

Historical Balance Sheet



Particulars	Mar-24	Mar-23
Non-Current assets		
Property, Plant and Equipments	434.9	348.6
Capital Work in Process	15.3	49.0
Intangible assets	17.8	13.8
Investments	20.6	15.4
Intangible assets under development	2.1	5.7
Financial Assets		
Loans	0.5	0.5
Other Non-Current Assets	18.3	17.2
Income tax assets	2.3	2.1
Total Non-Current Assets	511.8	452.3
Current Assets		
Inventories	83.6	73.0
Financial Assets		
Trade Receivables	111.7	88.8
Cash and Cash Equivalents	8.6	17.7
Loans	6.4	13.7
Other Current Assets	29.9	39.2
Current tax assets (Net)	0.0	0.0
Total Current Assets	240.3	232.4
Total Assets	752.1	684.6

Particulars	Mar-24	Mar-23
Equity		
Equity Share Capital	9.2	9.2
Other Equity	422.3	386.5
Total Equity	431.5	395.6
Non-Current Liabilities		
Financial Liabilities		
Long-term borrowings	69.8	62.5
Deferred tax liabilities (net)	20.4	16.9
Other long-term liabilities	1.2	1.2
Long-term provisions	2.2	2.3
Total Non-Current Liabilities	93.6	82.9
Current Liabilities		
Short-term borrowings	138.5	123.2
Trade payables	67.2	51.7
Other financial liabilities	10.3	10.4
Other current liabilities	9.7	19.5
Short-term provisions	1.3	1.2
Current tax liabilities (net)	0.0	0.0
Total Current Liabilities	227.0	206.1
Total Equity and Liabilities	752.1	684.6

On Standalone basis

Cash Flow Statement



Consolidated

Standalone

Particulars (Rs. Cr.)	FY24	FY23
Profit Before Tax	69.8	45.2
Adjustments	58.2	51.4
Operating profit before working capital changes	128.0	96.6
Changes in working capital	-27.0	-0.6
Cash generated from operations	101.0	96.0
Direct taxes paid (net of refund)	-8.8	-6.0
Net Cash from Operating Activities	92.3	90.0
Net Cash from Investing Activities	-99.0	-100.9
Net Cash from Financing Activities	9.8	-5.1
Net Change in cash and cash equivalents	3.1	-16.0
Add: Cash & Cash equivalents at the beginning of the period	19.1	35.1
Closing Cash Balance	22.2	19.1

FY24	FY23
48.7	40.1
56.2	50.4
104.8	90.5
-21.6	0.2
83.3	90.7
-8.8	-6.0
74.5	84.7
-92.4	-93.3
4.6	-5.1
-13.3	-13.7
17.7	31.4
4.4	17.7

Contact





SGA Strategic Growth Advisors

Company:

Shaily Engineering Plastics Ltd.

CIN - L51900GJ1980PLC065554

Mr. Sanjay Shah, Chief Strategy Officer sanjay@shaily.com

www.shaily.com

Investor Relations Advisors:

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Deven Dhruva

shogun.jain@sgapl.net / deven.dhruva@sgapl.net

+91 77383 77756 / +91 98333 73300

www.sgapl.net